ArticleJournal of neuro-oncology2026
Supplementary motor area syndrome in intracranial gliomas is not associated with worse survival.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeResection of gliomas involving the supplementary motor area (SMA) carries a substantial risk of postoperative functional deficits, which may affect patients' ability to undergo adjuvant therapy. This study evaluated whether postoperative SMA syndrome is associated with delayed initiation of adjuvant therapy and with progression-free survival (PFS) and overall survival (OS).
methodsWe performed a retrospective single-center study of patients undergoing resection of gliomas involving, adjacent to, or approached through the SMA between 2015 and 2024. SMA syndrome was defined as new-onset motor deficits and/or language impairment without corresponding intraoperative neuromonitoring changes and without involvement of the primary motor cortex or corticospinal tract. Logistic and Cox regression analyses were performed.
resultsSeventy-four patients were included, of whom 37 (50%) developed postoperative SMA syndrome. In univariate logistic regression, RANO class 2 A and class 2B resections were associated with higher odds of postoperative SMA syndrome compared with RANO class 1 resections (p = 0.048 and p = 0.035, respectively). In the pairwise multivariable model, grouped RANO class 2 resections remained associated with higher odds of postoperative SMA syndrome compared with class 1 resections (OR 5.05, 95% CI 1.24-20.57; p = 0.024). Postoperative SMA syndrome was not associated with delayed initiation of adjuvant therapy (HR 0.86, 95% CI 0.49-1.53; p = 0.617), PFS (HR 1.21, 95% CI 0.63-2.32; p = 0.573), or OS (HR 1.21, 95% CI 0.49-2.95; p = 0.681). Postoperative functional decline (≥ 20-point KPS decrease) was independently associated with receipt of modified or reduced-intensity adjuvant therapy (adjusted OR 13.91, 95% CI 2.21-87.64; p = 0.005), whereas SMA syndrome itself was not associated with treatment modification.
conclusionsPostoperative SMA syndrome was not associated with delayed adjuvant therapy or worse survival. Functional status, rather than SMA syndrome, influenced treatment intensity, supporting maximal safe resection in the SMA region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.